HBP On Other Exchanges
Symbol
Exchange
Toronto
OTC US
Frankfurt

helix biopharma corp (HBP) Snapshot

Open
--
Previous Close
--
Day High
--
Day Low
--
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
--
Average Volume 10 Days
--
EPS TTM
--
Shares Outstanding
--
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for HELIX BIOPHARMA CORP (HBP)
\

Related News

No related news articles were found.

helix biopharma corp (HBP) Related Businessweek News

No Related Businessweek News Found

helix biopharma corp (HBP) Details

Helix BioPharma Corp., an immune-oncology company, focuses on the development of cancer drugs in Canada. The company is developing L-DOS47 for the treatment of non-squamous small cell lung cancer, as well as for colon, pancreas, and breast cancer; V-DOS47 that targets the vascular epithelial growth factor receptor 2; and chimeric antigen receptor T-cell (CAR-T) therapeutic for the treatment of hematological and solid tumors. The company has collaboration agreement with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with ProMab Biotechnologies, Inc. to develop novel antibody and chimeric antigen receptor T-cell therapy for hematological malignancies, as well as a collaborative research agreement with Affilogic to assess proprietary anti-tumor targeting agents in combination with DOS47. Helix BioPharma Corp. is headquartered in Richmond Hill, Canada.

22 Employees
Last Reported Date: 10/26/18

helix biopharma corp (HBP) Top Compensated Officers

CEO, Chief Scientific Officer, Member of Scie...
Total Annual Compensation: C$298.8K
CFO & Corporate Secretary
Total Annual Compensation: C$283.3K
Compensation as of Fiscal Year 2018.
helix biopharma corp
Helix BioPharma Corp. Announces L-DOS47 Phase II Randomized Study Advances to Second Cohort

Helix BioPharma Corp. announced that the Trial Steering Committee ("TSC") reviewed safety data from the first dosing cohort of the Company’s LDOS003 study. No serious adverse events or dose limiting toxicities were observed. TSC recommended that Helix begin enrollment of patients into the second dosing cohort. LDOS003 is a Phase II, open-label, randomized study of immunoconjugate L-DOS47 in combination with vinorelbine and cisplatin as compared to vinorelbine and cisplatin alone in patients with lung adenocarcinoma. The study is divided into two parts. In part I, the maximum tolerated dose of L-DOS47, when given in combination with vinorelbine/cisplatin, will be determined. Cohorts of 3 patients will be recruited into three dosing cohorts (6, 9 and 12 µg/kg). All patients at a given dose level must complete the first treatment cycle (3-week period) before escalation in subsequent patients can proceed. In part II, after the maximum tolerated dose of L-DOS47 in combination with vinorelbine/cisplatin has been determined, a further 118 patients will be randomized (1:1) to receive L-DOS47 in combination with vinorelbine/cisplatin, or vinorelbine/cisplatin alone.

Helix Biopharma Corp. Proposes the Amendments to the Articles

Helix BioPharma Corp. announced at its annual and special meeting held on April 15, 2019, proposed the amendments to the articles of the company to consolidate the issued and outstanding Common Shares of Helix at a ratio of between five and twenty-five pre-consolidation Common Shares for every one post-consolidation Common Share, as and when determined by the Board of Directors.

Helix Biopharma Corp. Reports Earnings Results for the Second Quarter Ended January 31, 2019

Helix Biopharma Corp. announced earnings results for the second quarter ended January 31, 2019. For the second quarter, the company announced net loss was CAD 1.908 million compared to CAD 2.564 million a year ago. Basic loss per share was CAD 0.02 compared to CAD 0.03 a year ago. For the half year, net loss was CAD 3.287 million compared to CAD 4.868 million a year ago. Basic loss per share was CAD 0.03 compared to CAD 0.05 a year ago.

 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

HBP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for HBP.
View Industry Companies
 

Industry Analysis

HBP

Industry Average

Valuation HBP Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact HELIX BIOPHARMA CORP, please visit www.helixbiopharma.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.